全部分类
  • ALB-127158(a)
ALB-127158(a)的可视化放大

ALB-127158(a)

ALB-127158(a)是一种有效的选择性黑色素浓缩激素1(MCH1)受体拮抗剂。

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

ALB-127158(a)的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 5mg
    ¥2262.00
    1810.00
    - +
  • 10mg
    ¥3562.00
    2850.00
    - +
  • 25mg
    ¥6950.00
    5560.00
    - +
  • 50mg
    ¥11762.00
    9410.00
    - +
  • 100mg
    ¥19062.00
    15250.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajce47018
  • CAS: 1173154-32-9
  • 别名:
  • 分子式: C23H21FN4O2
  • 分子量: 404.44
  • 纯度: >98%
  • 溶解度: Ethanol : 2 mg/mL (4.95 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

ALB-127158(a) is a potent and selective melanin concentrating hormone 1 (MCH1) receptor antagonist.


ALB-127158(a) has high affinity for the MCH1 receptor (7 nM) with good selectivity over a range of other G-protein coupled receptors (GPCRs), ion channels and transporters, including the MCH2 receptor. In vitro functional assays confirmed that ALB-127158(a) is a potent and selective MCH1 receptor antagonist[1].


In a mouse diet induced obesity (DIO) model, ALB-127158(a) produces a significant sustained decrease in body weight and food intake in the range of 5-15 mg/kg bid. The weight reduction is predominantly due to a decrease in fat content. In high fat diet (HFD) rats, ALB-127158(a) produces significant weight loss and food reduction at doses as low as 1.25 mg/kg po. Doses > 1.25 mg/kg po produces weight loss > 6%, maximal weight loss of about 10% in rats is observed at 10 mg/kg. Following single and multiple oral administration of ALB-127158(a), ALB-127158(a) is rapidly absorbed (median tmax attains between 1 and 3 h post dose in lean and overweight/obese subjects) with a trend to decrease over dose suggesting a slower absorption rate of ALB-127158(a) at lower doses. After single doses, ALB-127158(a) has a mean half-life (t1/2) of 18 to 21 h. Slightly longer mean t1/2 estimates of approximately 26 h are obtained following multiple dosing in overweight/obese subjects; steady-state plasma ALB-127158(a) is attained within 6 to 8 days of dosing[1].


[1]. Moore NA, et al. From preclinical to clinical development: the example of a novel treatment for obesity. Neurobiol Dis. 2014 Jan;61:47-54.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算